1. Why Prosecution Speed Is a Balance Sheet Issue The 20-year patent term granted under 35 U.S.C. Section 154 is […]

Who this is for: Business development leads managing loss-of-exclusivity (LOE) timelines, IP counsel evaluating secondary patent thickets, portfolio managers modeling

The biosimilar first-mover question has a clean theoretical answer and a messy empirical one. Theory says: get to market first,

Executive Summary Generic pharmaceutical companies face a structural cost squeeze that has worsened since 2016. Teva, Mylan, and Sun Pharma

A deep-dive pillar page for pharma/biotech IP teams, R&D leads, and institutional investors. Part 1: The R&D Productivity Crisis —

Why Formulary Management Is Now an IP Discipline The pharmaceutical formulary started its modern life as an administrative cost control

The 80/80 Paradox: What the Numbers Actually Say The U.S. pharmaceutical market runs on a structural contradiction that no other

The United States pharmaceutical market operates within a network of opaque intermediaries that disconnect manufacturing costs from patient expenditures. Billionaire

1. Why Patent Defense Is a Corporate Strategy Problem, Not a Legal One Patent defense gets handed to legal teams.